TTR and cancer: There were no significant differences in TTR under different situations.<h4>Conclusions</h4>PD-1/PD-L1 inhibitors were promising immunotherapeutic agents to achieve satisfactory response efficacies with different cancer types, treatment lines, drug combinations, and therapeutic regimens.